MedCap AB/Skr MCAP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MedCap AB
MedCap AB, established in 2001 and headquartered in Stockholm, Sweden, is a private equity firm specializing in the acquisition and development of small to medium-sized companies within the life sciences sector. The firm focuses on three primary business areas: MedTech, Assistive Tech, and Specialty Pharma. MedCap's portfolio includes subsidiaries such as Abilia, which operates in assistive technology; Cardiolex, specializing in ECG solutions; and Unimedic, involved in specialty pharmaceuticals. The company primarily targets investments in Northern Europe, aiming to support businesses with international growth potential. MedCap typically acquires majority stakes, providing capital, expertise, and networks to foster long-term development.
- Ticker
- Skr MCAP
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 663
- Headquarters
- Stockholm, Sweden
- Website
- medcap.se/en
MedCap AB Metrics
BasicAdvanced
kr 8.3B
30.18
kr 18.30
0.47
-
Price and volume
Market cap
kr 8.3B
Beta
0.47
52-week high
kr 622.00
52-week low
kr 440.00
Average daily volume
23K
Financial strength
Current ratio
1.706
Quick ratio
1.165
Long term debt to equity
0.206
Total debt to equity
0.256
Interest coverage (TTM)
6.05%
Profitability
EBITDA (TTM)
509.2
Gross margin (TTM)
60.52%
Net profit margin (TTM)
11.55%
Operating margin (TTM)
16.30%
Effective tax rate (TTM)
21.98%
Revenue per employee (TTM)
kr 3,580,000
Management effectiveness
Return on assets (TTM)
9.16%
Return on equity (TTM)
17.64%
Valuation
Price to earnings (TTM)
30.184
Price to revenue (TTM)
3.486
Price to book
4.85
Price to tangible book (TTM)
26.41
Price to free cash flow (TTM)
23.466
Free cash flow yield (TTM)
4.26%
Free cash flow per share (TTM)
23.545
Growth
Revenue change (TTM)
18.59%
Earnings per share change (TTM)
39.02%
3-year revenue growth (CAGR)
17.76%
3-year earnings per share growth (CAGR)
21.92%
What the Analysts think about MedCap AB
Analyst ratings (Buy, Hold, Sell) for MedCap AB stock.
Analyst projections of the future price of MedCap AB stock.
Bulls say / Bears say
Third-quarter sales rose 13% and adjusted EBITA increased 30%, with the adjusted margin up to 20.9% from 18.2%. All three business areas contributed, showing that profit growth was broad-based. (MedCap)
Only three of the 20 products added through XGX Pharma have been launched, leaving scope for further growth as the pipeline is commercialised and products reach more markets. Management expects Specialty Pharma’s margin to strengthen as this progresses. (MedCap)
Net debt excluding lease liabilities was SEK64 million, equal to just 0.1 times EBITDA. The low leverage gives MedCap capacity to pursue further acquisitions without relying heavily on new borrowing. (MedCap)
Organic sales growth was 5% in the third quarter, well below the 13% headline increase, which also included acquisitions. ECG sales fell against a strong comparison and a couple of Assistive Tech businesses grew more weakly. (MedCap)
Adjusted earnings per share were unchanged at SEK10.6 for the first nine months, despite adjusted EBITA rising 29%. In the third quarter, adjusted earnings per share fell to SEK2.3 from SEK3.6, so operating growth has not yet translated into stronger adjusted earnings per share. (MedCap)
Specialty Pharma’s quarterly sales growth relied mainly on the XGX acquisition and higher non-recurring sales of unlicensed medicines. With only three of XGX’s 20 pipeline products launched so far, the expected improvement depends on successful launches and may take time to deliver. (MedCap)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
MedCap AB Financial Performance
Revenues and expenses
MedCap AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing MedCap AB
Fund name | Fund size | Skr MCAP weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.04% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.04% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.